Summary & Overview

HCPCS G6041: Alkaloids, Urine, Quantitative

HCPCS Level II code G6041 denotes a quantitative urine assay for alkaloids, used to measure specific alkaloid compounds for clinical evaluation of exposure, toxicity, or therapeutic monitoring. Nationally, standardized lab coding for specialized biochemical assays like alkaloid quantification supports consistent billing, data capture, and clinical decision-making across laboratory and hospital settings. This code is relevant where metabolic, toxicologic, or pharmacologic assessments involve alkaloid compounds.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national overview of how G6041 is classified and used in clinical billing, context on typical sites of service (clinical and hospital laboratories), and the common clinical reasons such testing is ordered. The publication summarizes available benchmarks and payer coverage patterns where applicable, highlights any notable policy updates affecting laboratory coding and billing for specialized assays, and explains related clinical context for interpretation of quantitative urine alkaloid results.

This summary is intended for billing professionals, laboratory managers, and policy analysts seeking a concise briefing on the clinical and billing significance of G6041 at a national level. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG6041HCPCS Level IIurine laboratoryalkaloidsquantitative assaytoxicologyclinical laboratorybilling codelaboratory billing

Billing Code Overview

HCPCS Level II code G6041 represents Alkaloids, urine, quantitative. This code covers laboratory testing that measures concentrations of alkaloid compounds in a urine specimen, typically performed to assess exposure, toxicity, or therapeutic monitoring where alkaloid levels are clinically relevant.

Service type: Laboratory quantitative urine analysis

Typical site of service: Clinical laboratory or hospital laboratory

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 34-year-old patient presents to an outpatient toxicology clinic with symptoms of acute agitation, tachycardia, and altered mental status after potential exposure to plant-derived alkaloids or suspected overdose of an alkaloid-containing substance. The clinician orders a quantitative urine alkaloid assay to measure concentrations of specific alkaloids (for example, atropine, scopolamine, cocaine alkaloids, or ergot alkaloids) to confirm exposure, guide supportive care, and document levels for toxicology reporting.

The clinical workflow begins with the ordering provider (emergency physician, toxicologist, or primary care physician) entering the test as G6041 on the laboratory requisition. A urine specimen is collected in a sterile container, labeled with patient identifiers, and transported to the clinical laboratory. The laboratory performs the quantitative analysis using validated methods (e.g., GC-MS, LC-MS/MS). The technologist documents the technical component (modifier TC when billing separates technical from professional components). Results are reviewed by a pathologist or clinical chemist, interpreted in context of clinical findings, and reported back to the ordering clinician for patient management. Typical sites of service include outpatient laboratories, hospital laboratories, emergency departments, and specialty toxicology clinics.

Coding Specifications

Modifier	Description	When to Use
`TC`	Technical component	Use when billing only the laboratory technical portion (instrumentation, specimen processing) of the test.
`26`	Professional component	Use when billing only the professional reporting/interpretation component (if separate billing applies).
`90`	Reference laboratory	Use when the service is performed by an outside reference laboratory on behalf of the ordering provider.
`91`	Repeat clinical diagnostic laboratory test	Use when the specimen is repeatedly tested on the same day for validation or verification purposes.
`QW`	CLIA waived test	Not typically applicable to quantitative alkaloid assays; use if a waived-method variant exists (rare).
`59`	Distinct procedural service	Use when the quantitative alkaloid assay is a distinct service from other laboratory tests performed on the same day and requires separate reporting.
`GC`	Item/service provided in part by another physician of the same group	Use when a group practice splits components between physicians and needs to indicate shared provision.
`RE`	Renewal of medication, device, supply, or service	Use when indexing a repeat order related to prior authorization renewal processes (rare in lab billing workflows).
`24`	Unrelated E/M service by same physician during postoperative period	Use if an unrelated evaluation occurs the same day as the test and needs separate billing (rarely applicable to labs).
`26`	Professional component (repeat entry for emphasis)	See above—used when the interpretation/reporting is billed separately from the lab's technical work.

Taxonomy Code	Specialty	Notes
207Q00000X	Medical Toxicology	Specialists who interpret toxicology results and manage poisoning/exposure cases.
207L00000X	Pathology	Pathologists oversee clinical laboratory testing, validation, and result interpretation.
207K00000X	Clinical Laboratory	Laboratory medicine specialists and directors responsible for test performance and quality.
208D00000X	Emergency Medicine	Emergency physicians who commonly order acute toxicology testing in ED settings.
207P00000X	Psychiatry & Neurology (Clinical Neurophysiology context)	Clinicians who may order alkaloid testing when neuropsychiatric symptoms suggest toxic exposure.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`T44.7X5A`	Poisoning by other anticholinergics, accidental (initial encounter)	Anticholinergic alkaloids (e.g., atropine, scopolamine) can cause poisoning requiring quantitative urine alkaloid measurement.
`T40.5X1A`	Poisoning by cocaine, accidental (initial encounter)	Cocaine is an alkaloid; quantitative urine alkaloid testing can identify and measure cocaine exposure in suspected overdoses.
`T43.6X1A`	Poisoning by psychostimulants with abuse potential, accidental (initial encounter)	Some plant-derived stimulants contain alkaloids; quantitative testing assists in confirming exposure.
`R41.82`	Altered mental status, unspecified	Patients with altered mental status of unclear cause may undergo alkaloid testing as part of a toxicology workup.
`F10.20`	Alcohol dependence, uncomplicated	Concurrent substance use disorders may prompt broader toxicology panels including alkaloid quantification.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80307`	Drug test, qualitative; multiple drug classes by high complexity test method	Performed alongside quantitative alkaloid testing to screen for presence of common drug classes prior to confirmatory quantitative assays.
`80305`	Drug test, presumptive, any number of drug classes; automated analyzer screen	Used as an initial screening test in the workflow before ordering quantitative confirmatory testing such as `G6041`.
`80320`	Drug confirmation, quantitative; each drug class	Employed for confirmatory quantitative measurement of specific drugs or metabolites using GC-MS or LC-MS/MS complementary to alkaloid quantification.
`80318`	Drug confirmation, quantitative; by mass spectrometry	Common method-based CPT for quantitative confirmatory testing that may occur for specific alkaloids when a CPT-level code is required.
`80053`	Comprehensive metabolic panel	Routine laboratory panel often ordered concurrently to assess end-organ effects in patients with toxic exposures.